These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
45. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy. Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933 [TBL] [Abstract][Full Text] [Related]
46. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor? Schneider EK; Reyes-Ortega F; Li J; Velkov T Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127 [TBL] [Abstract][Full Text] [Related]
47. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis. Mayer-Hamblett N; Boyle M; VanDevanter D Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594 [TBL] [Abstract][Full Text] [Related]
49. Breathing easier with combinations. Azvolinsky A Nat Biotechnol; 2015 Nov; 33(11):1128-30. PubMed ID: 26544137 [No Abstract] [Full Text] [Related]
50. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry. Elborn JS; Ramsey B; Wainwright C; Boyle M Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855 [No Abstract] [Full Text] [Related]
51. [Cystic fibrosis: new treatments targeting the CFTR protein]. Fajac I; Sermet-Gaudelus I Rev Mal Respir; 2013 Apr; 30(4):255-61. PubMed ID: 23664284 [TBL] [Abstract][Full Text] [Related]
52. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
53. Hot off the breath: 'I've a cost for'--the 64 million dollar question. Bush A; Simmonds NJ Thorax; 2012 May; 67(5):382-4. PubMed ID: 22407889 [No Abstract] [Full Text] [Related]
54. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation. Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139 [TBL] [Abstract][Full Text] [Related]
56. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
57. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review. Dryden C; Wilkinson J; Young D; Brooker RJ; Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428 [TBL] [Abstract][Full Text] [Related]
58. The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial. Durmowicz AG; Lim R; Rogers H; Rosebraugh CJ; Chowdhury BA Ann Am Thorac Soc; 2018 Jan; 15(1):1-2. PubMed ID: 29020455 [TBL] [Abstract][Full Text] [Related]
59. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related]
60. Cystic fibrosis in an era of genomically guided therapy. Barrett PM; Alagely A; Topol EJ Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]